177Lu-vipivotide tetraxetan is a radiopharmaceutical that selectively targets prostate-specific membrane antigen (PSMA) and delivers beta-radiations to kill prostate cancer cells.
Extensive experience outside the United States as well as randomized phase II and phase III data demonstrate that 177Lu-vipivotide tetraxetan is a safe, generally well-tolerated and effective therapy for men with mCRPC. 177Lu-vipivotide tetraxetan was approved by the FDA in March of 2022 for the treatment of PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) after androgen receptor pathway inhibition and taxane-based chemotherapy based on the results of the VISION trial.
This review discusses the development and studies leading to the approval of 177Lu-vipivotide tetraxetan. In all, 177Lu-vipivotide tetraxetan is an exciting new tool in the arsenal for men with mCRPC after novel androgen pathway inhibitors and at least one taxane chemotherapy. Optimal selection of patients, sequencing of 177Lu-vipivotide tetraxetan with the other agents available to treat mCRPC, and the use of dosimetry are current areas of interest with great potential and opportunities for further individual patient optimization using the tools of theranostics.
Expert review of anticancer therapy. 2022 Oct 28 [Epub ahead of print]
Hina Shah, Praful Ravi, Guru Sonpavde, Heather Jacene
Department of Imaging, Dana-Farber Cancer Institute, Boston, MA., The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA.